Clinical trial
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of…
NCT02362594 · Merck Sharp & Dohme LLC, Industry · Active, not recruiting
Key facts
| NCT number | NCT02362594 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) |
| Official title | Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | European Organisation for Research and Treatment of Cancer |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological, Drug |
| Interventions | pembrolizumab, placebo |
| Enrollment | 1,019 |
| Start date | Jul 16, 2015 |
| Primary completion | Jan 8, 2018 |
| Completion | Nov 1, 2026 |
| First posted | Feb 13, 2015 |
| Last update posted | Oct 15, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: